Scudla V, Ordeltová M, Spidlová A, Bacovský J, Budíková M, Srovnalík K
III. interní klinika LF UP a FN, Olomouc.
Vnitr Lek. 1999 Jun;45(6):336-41.
The authors evaluated in a group of 50 patients with multiple myeloma (MM), examined when the diagnosis was established before onset of treatment, and in a group of 85 patients examined in different stages of MM the relationship of proliferative characteristics of myeloma plasmocytes assessed by means of the propidium-iodide index PI/CD38, PI/"UHKT" and PI/B-B4(CD138) with the progression, "performance status" and the activity of the disease. With the exception of a different value of the PI/CD38 index between stages 1 and 3 evaluated according to Durie-Salmon, in the whole group of patients no relationship was found with the progress of the disease. When evaluating the whole group the authors observed a difference between sub-stages A and B (i.e. between patients without and with a serious impairment of renal function) when using indexes PI/CD38 and PI/B-B4(CD138). Only in the whole group of 85 patients the authors found a significant relationship of all proliferation indexes (PI/CD38PI/"UHKT" and PI/B-B4) with the "performance status" according to ECOG score to or > or = 3 vs. < 3. In both groups there was a very close statistically significant relationship without the activity of the disease whichever of the three proliferation indexes was used. It was revealed that patients with the active but stable form of the disease have different PI/CD38 and PI/B-B4(CD138) indexes within the framework of the same stage of MM (stages 1 + 2 vs. 3). From the investigation ensues that examination of the PI proliferation index, in particular PI/B-B4(CD138) or possibly PI/CD38 using multiparametric flow cytometry is a valuable method extending hitherto used examination procedures in MM, and that it replaces adequately former autoradiographic and microscopic immunofluorescent techniques.
作者在一组50例多发性骨髓瘤（MM）患者中进行了评估，这些患者在治疗开始前确诊时接受检查，同时在一组85例处于MM不同阶段的患者中，研究了通过碘化丙啶指数PI/CD38、PI/"UHKT"和PI/B - B4(CD138)评估的骨髓瘤浆细胞增殖特征与疾病进展、“体能状态”和疾病活动度之间的关系。除了根据Durie - Salmon标准评估的1期和3期之间PI/CD38指数值不同外，在整个患者组中未发现与疾病进展的关系。在评估整个组时，作者在使用PI/CD38和PI/B - B4(CD138)指数时观察到A和B亚阶段（即肾功能无严重损害和有严重损害的患者之间）存在差异。仅在85例患者的整个组中，作者发现所有增殖指数（PI/CD38、PI/"UHKT"和PI/B - B4）与根据ECOG评分3级及以上与低于3级的“体能状态”之间存在显著关系。在两组中，无论使用三种增殖指数中的哪一种，都与疾病活动度存在非常密切的统计学显著关系。结果显示，处于疾病活跃但稳定形式的患者在MM同一阶段（1 + 2期与3期）范围内具有不同的PI/CD38和PI/B - B4(CD138)指数。从该研究得出，使用多参数流式细胞术检测PI增殖指数，特别是PI/B - B4(CD138)或可能的PI/CD38，是一种有价值的方法，扩展了迄今在MM中使用的检测程序，并且它充分替代了以前的放射自显影和显微镜免疫荧光技术。
